NanoViricides Announces Promising Measles Treatment

NanoViricides, Inc. has announced that its drug candidate NV-387 shows strong activity against the Measles virus. With over 1,600 cases recently reported in the USA, the need for effective treatment is urgent. NV-387, which demonstrated success in animal models, is now available for emergency use in Measles patients.

NV-387 has already completed a Phase I clinical trial with no adverse events reported. In animal studies, it significantly increased survival times, indicating a strong potential for human applications. The drug offers a novel mechanism by attacking and destroying virus particles and is available as oral gummies, easing administration for patients.

The company supports physician-initiated applications for emergency use, recognizing the growing challenge as the Measles virus evolves and vaccination rates fall short. NV-387 is underdevelopment for treating various respiratory viruses alongside its current focus on Measles.